TD Asset Management Inc Buys 57,912 Shares of Immunome, Inc. $IMNM

TD Asset Management Inc grew its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 8.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 759,192 shares of the company’s stock after acquiring an additional 57,912 shares during the period. TD Asset Management Inc owned about 0.69% of Immunome worth $16,307,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Strs Ohio bought a new stake in shares of Immunome during the fourth quarter valued at approximately $64,000. Assetmark Inc. purchased a new position in Immunome in the third quarter worth $39,000. BIT Capital GmbH purchased a new position in Immunome in the third quarter worth $69,000. BNP Paribas Financial Markets grew its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Immunome in the third quarter worth $76,000. Institutional investors own 44.58% of the company’s stock.

Analyst Ratings Changes

IMNM has been the topic of several analyst reports. Craig Hallum lifted their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Stephens cut their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Leerink Partners cut their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Truist Financial lifted their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Immunome has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Insider Buying and Selling at Immunome

In other Immunome news, Director Philip Wagenheim sold 28,200 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $20.65, for a total value of $582,330.00. Following the completion of the transaction, the director owned 341,147 shares in the company, valued at approximately $7,044,685.55. This represents a 7.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jean Jacques Bienaime acquired 5,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.70 per share, with a total value of $103,500.00. Following the transaction, the director owned 43,415 shares of the company’s stock, valued at approximately $898,690.50. This trade represents a 13.02% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 139,438 shares of company stock valued at $2,964,664 in the last three months. Company insiders own 7.21% of the company’s stock.

Immunome Stock Performance

NASDAQ:IMNM opened at $18.61 on Tuesday. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -7.82 and a beta of 2.04. The firm’s fifty day moving average is $21.97 and its two-hundred day moving average is $21.70.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, equities research analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.